1. Immunology/Inflammation
  2. CD3

CD3

CD3 (cluster of differentiation 3) is a protein complex and T cell co-receptor that is involved in activating both the cytotoxic T cell (CD8+ naive T cells) and T helper cells (CD4+ naive T cells). It is composed of four distinct chains. In mammals, the complex contains a CD3γ chain, a CD3δ chain, and two CD3ε chains. These chains associate with the T-cell receptor (TCR) and the CD3-zeta (ζ-chain) to generate an activation signal in T lymphocytes. The TCR, CD3-zeta, and the other CD3 molecules together constitute the TCR complex.

CD3 Related Products (74):

Cat. No. Product Name Effect Purity
  • HY-P99931
    Epcoritamab 99.84%
    Epcoritamab (GEN3013) is an bispecific IgG1 antibody redirecting T-cells toward CD3×CD20+ tumor cells. Epcoritamab induces potent T-cell-mediated cytotoxicity towards B-cell NHL cell lines[1].
  • HY-P99394
    Talquetamab 98.52%
    Talquetamab (JNJ-64407564) is a humanized bispecific antibody that binds to GPRC5D (member of G protein-coupled receptor family C5 group D) and CD3 to induce T cell-mediated killing of GPRC5D-expressing MM cells through T cell recruitment and activation. Talquetamab (JNJ-64407564) has antitumor activity[1][2].
  • HY-P99033
    Mosunetuzumab Inhibitor 99.05%
    Mosunetuzumab (BTCT-4465A) is a full-length, fully humanized immunoglobulin G1 (IgG1) T-cell-dependent bispecific (TDB) antibody targeting CD20 (B cells) and CD3 (T cells). Mosunetuzumab redirects T cells to engage and eliminate malignant B cells and can be used for the research of relapsed or refractory (R/R) B-cell non-Hodgkin lymphomas (B-NHLs)[1][2].
  • HY-P99024
    Glofitamab
    Glofitamab (RO7082859) is a T-cell-engaging bispecific antibody possessing a novel 2:1 structure with bivalency for CD20 on B cells and monovalency for CD3 on T cells. Glofitamab leads to T-cell activation, proliferation, and tumor cell killing upon binding to CD20 on malignant cells. Glofitamab induces durable complete remissions in relapsed or refractory B-Cell non-Hodgkin lymphoma (B-NHL)[1][2][3][4].
  • HY-P99392
    Teclistamab 99.87%
    Teclistamab is a human bispecific antibody to BCMA and CD3 that recognizes BCMA on target cells and CD3 on T cells and induces T cell-mediated cytotoxicity leading to T cell activation and subsequent target cell lysis. Teclistamab can be used in studies of diseases related to multiple myeloma (MM)[1].
  • HY-P991172
    JNJ-70218902
    JNJ-70218902 is a bispecific antibody that binds to human TMEFF2 on cancer cells and to human CD3 on T cells. JNJ-70218902 induces an exposure-dependent proinflammatory response and targeted tumor cell lysis, and promotes T cell-mediated tumor cell killing (EC50: 1.4 nM). JNJ-70218902 has a promising potential for prostate cancer research. The recommended isotype control is human IgG4 kappa, isotype control (HY-P99003)[1].
  • HY-P991209
    Nebratamig Inhibitor
    Nebratamig is an anti-ROR1/anti-CD3/anti-PD-L1/anti-4-1BB tetra-specific antibody with potential immunostimulatory and antineoplastic activities[1].
  • HY-P991163
    Tixentamig Inhibitor
    Tixentamig is a bispecific monoclonal antibody targeting human CD3 ε and CLDN18 (claudin 18). Tixentamig is promising for research of cancers[1].
  • HY-P990925
    Linclatamig Inhibitor
    HY-P990925 is an CD3E-targeting IgG1κ type humanized antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001)[1].
  • HY-P990095
    Vonsetamig Inhibitor
    Vonsetamig is a humanised immunoglobulin G4-kappa, anti-TNFRSF17 and CD3E bispecific antibody. Vonsetamig is an antineoplastic[1].
  • HY-P990920
    Gocatamig Inhibitor
    HY-P990920 is an CD3E/ALB/DLL3-targeting (scFv-heavy-lamdba)-VH-VH' type chimeric humanized antibody[1].
  • HY-P99757
    Nivatrotamab Inhibitor 99.40%
    Nivatrotamab (Hu3F8-BsAb) is a humanized anti-GD2/CD3 bispecific antibody. Nivatrotamab is a CD3- and GD2-specific bsAb-based T-cell engager. Nivatrotamab can be used in research of neuroblastoma[1].
  • HY-P990717
    Brenetafusp Inhibitor
    Brenetafusp is an anti-CD3E/PRAME monoclonal antibody[1].
  • HY-P99199
    Foralumab 98.08%
    Foralumab (NI-0401) is a potent, orally active human monoclonal antibody targeting the CD3. Foralumab modulates immune responses by human cells in NSG mice that were reconstituted with human hematopoietic stem cells[1].
  • HY-P991088
    HPN536 Inhibitor
    HPN536 is a trispecific, T-cell-activating protein-based construct, which binds to mesothelin-expressing tumor cells, CD3ε on T cells, and to serum albumin. HPN536 specifically redirects T cells for potent redirected lysis of mesothelin-expressing cancer cells with concomitant T-cell activation[1].
  • HY-P99798
    Pacanalotamab Chemical
    Pacanalotamab (AMG 420; BI-836909) is a bispecific T-cell engager (BiTE) targeting to BCMA and CD3E. BCMA refers to B cell maturation antigen, as Pacanalotamab redirecting T cells to BCMA expressing cells on the cell surface. Pacanalotamab conducts T-cell redirected lysis of human multiple myeloma (MM) cell lines[1].
  • HY-P991197
    Anti-GPRC5D Antibody Inhibitor
    Anti-GPRC5D Antibody is a humanized IgG1 monoclonal antibody that targets GPRC5D. Anti-GPRC5D Antibody is the antibody part of the ADC molecule LM-305. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
  • HY-P990802
    Anti-Mouse CD3ε Antibody (145-2C11) Inhibitor
    Anti-Mouse CD3ε Antibody (145-2C11) is a kind of Armenian hamster IgG1 in vivo mouse antibody, targeting to CD3ε. The recommend isotype control of Anti-Mouse CD3ε Antibody (145-2C11): Armenian hamster IgG, Isotype Control (HY-P990305).
  • HY-P990862
    Anti-CD326/EpCAM Antibody (Ber-EP4)
    Anti-CD326/EpCAM Antibody (Ber-EP4) is a kind of mouse IgG1, κ chimeric antibody, targeting to human CD326/EpCAM. The recommend isotype control of Anti-CD326/EpCAM Antibody (Ber-EP4): Mouse IgG1 kappa, Isotype Control (HY-P99977).
  • HY-P99222
    Teplizumab
    Teplizumab (MGA-031) is a Fc receptor non-binding anti-human CD3 monoclonal antibody. Teplizumab reduces the loss of beta-cell function. Teplizumab can be used in the research of type 1 diabetes[1][2].